Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
DEXAMETHASONE VIATRIS dexamethasone phosphate (as dexamethasone sodium phosphate) 8 mg/2 mL solution for injection vial, Alphapharm Pty Ltd, CON-1105
Product name
DEXAMETHASONE VIATRIS dexamethasone phosphate (as dexamethasone sodium phosphate) 8 mg/2 mL solution for injection vial
Sponsor name
Alphapharm Pty Ltd
Consent start
Consent no.
CON-1105
Standard
The product does not meet the pH requirements in the monograph for Dexamethasone Sodium Phosphate Injection of British Pharmacopoeia
Non-compliance with standard
Does not meet the pH requirements in the monograph
Conditions imposed
1. 'Dear Healthcare Provider' letters identical to those provided to the
Therapeutic Goods Administration on 24 April 2023 will be supplied with each
affected batch;
2. The Therapeutics Goods Administration must be informed immediately by writing
to the decision delegate if any batch of the product(s) is analysed and the
results obtained for pH are greater than or equal to pH 9.0.
Therapeutic product type
Prescription medicines